Reuters: Health
Novartis said on Wednesday that an older leukaemia drug it is re-purposing for multiple sclerosis halted disease activity in many patients during the first two years of injections as the Swiss drugmaker takes aim at Roche's lucrative Ocrevus infusion.
No comments:
Post a Comment